Tag Archives: ERS

7 International Congresses that Are Taking Place this Fall in the Medical World

The Annual Congress of European Respiratory Society (ERS 2018)

The ERS International Congress will take place in Paris, between 15-19 September. It is considered to be the largest meeting dedicated to respiratory professionals in the world. The scientific and educational programme caters to the needs of researchers, clinicians, general practitioners and allied health professionals alike.

For up-to-date information related to the ERS Congress, visit their website.

For accommodation offers – over 615 rooms in 20 exceptional hotels – visit our website.

 

The 18th European Society of Retina Specialists Congress (EURETINA 2018)

This year, the EURETINA Congress will take place in Vienna, between 20-23 September. EURETINA was established as a society dedicated to promoting knowledge among vitreoretinal and macula specialists in 1999. Their first congress took place in 2001 when it had around 200 participants, reaching over 5000 participants in recent years.

For up-to-date information related to the EURETINA Congress, visit their website.

For accommodation offers – over 460 rooms in 12 exceptional hotels – visit our website.

 

The 36th Congress of The European Society of Cataract and Refractive Surgeons (ESCRS 2018)

The 36th Congress of the ESCRS will take place between 22 – 26 September, in Vienna, Austria.

Founded in 1991, the ESCRS has since then promoted education and research in the field of implant and refractive surgery, as well as the study and practice of ophthalmology. ESCRS has over 7,500 members from 130 countries worldwide.

For up-to-date information related to the ESCRS Congress, visit their website.

For accommodation offers – over 360 rooms in 11 exceptional hotels – visit our website.

 

The 54th European Association for the Study of Diabetes Annual Meeting (EASD 2018)

The 2018 edition of the EASD Congress takes place between 1 – 5 October in Berlin, Germany.

The European Association for the Study of Diabetes (EASD) was founded in 1965 as a non-profit, medical scientific association. It is one of the largest networks for diabetologists worldwide with more than 5,000 active members from over 100 countries. EASD’s Annual Meeting takes place in a different European city each year with more than 15,000 delegates from over 130 countries attending.

For up-to-date information related to the EASD Congress, visit their website.

For accommodation offers – over 765 rooms in 16 exceptional hotels – visit our website.

 

The 34th European Committee for Treatment and Research in Multiple Sclerosis Congress (ECTRIMS 2018)

Between 10-12 October, in Berlin, Germany, ECTRIMS hosts the world’s largest annual international conference around basic and clinical research in multiple sclerosis.

For up-to-date information related to the ECTRIMS Congress, visit their website.

For accommodation offers – over 670 rooms in 11 exceptional hotels – visit our website.

 

The European Society for Medical Oncology Congress (ESMO 2018)

The ESMO 2018 Congress will take place between 19-23 October in Munich, Germany.

ESMO was founded in 1975 and has since become the leading European professional organisation for medical oncology, with over 18,000 oncology professionals from more than 150 countries.

For up-to-date information related to the ESMO Congress, visit their website.

For accommodation offers – over 1102 rooms in 21 exceptional hotels – visit our website.

 

The 26th United European Gastroenterology Week (UEGW 2018)

The UEG Week will take place between 20-24 October, in Vienna, Austria. Multidisciplinarity is a key focus of UEG Week, which covers topics of interest for the entire GI community.

The United European Gastroenterology is a professional non-profit organisation combining all the leading European societies concerned with digestive health – more than 25,000 specialists from every field in gastroenterology.

For up-to-date information related to the UEG Week, visit their website.

For accommodation offers – over 365 rooms in 8 exceptional hotels – visit our website.

 

logo-congress bookers

About Congress Bookers

In the world of MICE (Meetings, Incentives, Conferences and Events), Congress Bookers provides a whole range of services needed to organize a group for a medical congress. On our website, you will find a full list of hotel allotments for the most important medical congresses in 2018, regardless of their location. We operate internationally!

Advertisements

Let’s Meet at ESMO, ERS, EASD and EADV Congresses in September

These are last month’s pharma news and developments brought to you by Congress Bookers, a reliable accommodation partner for lead pharma companies worldwide.

We’ve finished drafting the agenda for the last 4 months of 2017. Time flies, doesn’t it? 🙂

 

In September, we will be on-site at the biggest and most well-known medical congresses in Europe: ESMO 2017, the ERS International Congress, EASD 2017 and the 26th EADV Congress. Congress Bookers will be there to showcase its booking offers for medical congresses in 2018 and beyond. If you also happen to be present at any of these congresses, let’s meet!

Now, here’s some information regarding the above mentioned congresses:

ESMO 2017 – 8-12 September | Madrid, Spain

Bringing together cancer researchers and clinicians, the ESMO 2017 Congress is being held in partnership with the European Association for Cancer Research (EACR). ESMO is considered to be “the most influential annual meeting for oncology professionals in Europe.”

You can see the online programme here.

 

ERS International Congress 2017 – 9-13 September | Milan, Italy

The ERS International Congress is considered to be “the largest meeting of respiratory professionals in the world.” Its scientific and educational programme addresses the needs of researchers, clinicians, general practitioners and health professionals worldwide.

You can see the online programme here.

 

EASD 2017 – 11-15 September | Lisbon, Portugal

The European Association for the Study of Diabetes (EASD) is a non-profit, medical scientific association founded in 1965 and headquartered in Duesseldorf, Germany. EASD holds its Annual Meeting in a different European city each year. Over 15,000 delegates from over 130 countries attend the event. The scientific programme includes presentations on the latest results in diabetes research.

You can see the online programme here.

 

The 26th EADV Congress – 13-17 September | Geneva, Switzerland

EADV was founded in 1987 as a non-profit association. Its mission is to advance excellence in clinical care, research, education and training in the fields of Dermatology and Venereology.

Every year, EADV organizes one main congress in one of the European capital cities and one spring meeting.

You can see the online programme of its 26th Congress here.

See you there!
cb-01

Congress Bookers provides a whole range of services needed to organize a group for a medical congress. On our website, you will find a full list of hotel allotments for the most important medical congresses in 2017 and 2018, regardless of their location. The biggest congresses next year are:

  • EASL 2018 – 210 rooms in seven 4-star hotels
  • EAACI 2018 – 615 rooms in fourteen 4-star hotels
  • EHA 2018 – 1200 rooms in thirty 4-star hotels
  • ERS 2018 – 615 rooms in twenty 4-star hotels
  • EURETINA 2018 – 460 rooms in twelve 4-star hotels
  • EASD 2018 – 765 rooms in sixteen 4-star hotels
  • ECTRIMS 2018 – 620 rooms in ten hotels
  • ESMO 2018 – 1092 rooms in twenty-one 4-star hotels.

How Pharma Companies Could Use Artificial Intelligence

Artificial intelligence is considered to be one of the hottest trends and innovations in the pharma landscape. Given that AI can be used to analyse and process large amounts of data, it is highly employed in research areas. AI can churn through huge amounts of data and find valuable information, something that can’t be done with conventional computers. Since the vastest part of pharma is related to research, AI couldn’t have been overlooked. Actually, although it holds many promises for the future, AI is already being used by big pharma companies. Its potential lies in several areas. Some of them are mentioned and tackled in this article.

pharma-companies-could-use-artificial-intelligence

Enhanced Drug Discovery

AI’s ability to analyse and process vast amounts of scientific data ranging from medical journals to patient records, biological samples and even blood tests is probably the most useful application of artificial intelligence in pharma. AI can guide pharma companies’ drug development endeavours by gathering and using patterns in the data to make scientific hypotheses, something that wouldn’t be possible with an ordinary computer.

With the help of artificial intelligence, the pharma sector can replace the tedious approach of chemical screening with AI-researched and highly accurate biological markers, therefore improving the drug to the highest extent possible, focusing on particular indications that it will treat.

Interrogative Biology is the platform of Boston-based biopharma BERG and it can look at 14 trillion data points in a single tissue sample. The company’s CEO Niven R. Narain believes that AI will cut the amount of time and the costs of bringing its lead molecule BPM 31510 to market in half. Using this approach, BERG’s team discovered the key role mitochondria had in allowing cancer cells to flourish in pancreatic cancer. BERG’s drug BPM 31510 helps the mitochondria function and turns the cancer cells back into normal cells.

On a different front, there is IBM’s Watson supercomputer that, as part of different trials, could scan mutation data from the tumours of 20 brain cancer patients. Something that would probably take humans months to analyse is only taking a few minutes with Watson’s help.

Eve, the University of Manchester’s AI platform, can screen more than 10,000 compounds in a day. Through machine learning and hypothesis testing, Eve improves her screening process based on the “learnings” from previous attempts.

Insilico Medicine is a bioinformatics company that uses AI to identify geroprotectors predicted to support human longevity. Its AI system can predict the therapeutic use of new drugs before they enter the testing process by processing vast amounts of data from experiments on human cells using known drugs.

 

Simplified Business Processes

AI can help pharma companies way beyond the drug discovery process, into the trial process and even up to business restructuring. In what concerns clinical trials, artificial intelligence could help enhance their effectiveness by quickly analysing the data which would have taken months for human scientists to fathom.

Artificial intelligence could also prove to be an asset when it comes to mergers and acquisitions in the pharma landscape. These happen a lot nowadays and it’s getting more and more challenging to find out and decide which combination is worthwhile. After a merger takes place, integrating R&D departments (which involve astounding amounts of information and research) can also be facilitated through the use of AI.

 

Streamlined ROI and Reduced Prices

Dr Andree Bates, President of Eularis, a pharmaceutical Artificial Intelligence analytics platform, said: “Think of how long it took from the beginning to launch Herceptin – the research prior to clinical trials was 10 years, followed by another 8 years for clinical trials. What AI can do is potentially reduce that process down to weeks.”

Cheaper drug development should lead to lower prices. Since drug pricing spikes are usually justified by huge R&D costs, lowering the latter should lead to a fall in drug prices and a clean reputation for pharma companies that have to deal with a lot of pressure when it comes to the matter of costs.

The great part about AI is not only that it becomes better with every attempt or use but that

even its “wrong” answers prove helpful by pointing at secondary uses for drugs that researchers hadn’t thought of.

Although we’re barely at the beginning of the application of AI in pharma, the promise exists and is set to change the ways in which drugs are made and brought to market. Whether it’s used for analysing data or in order to make a better business decision, artificial intelligence will enable big changes for pharma companies and patients alike.

 

If you’re passionate about artificial intelligence and innovations in pharma and healthcare, these congresses should be on your list in 2017:

4 Emerging Trends and Innovations in Pharma & Healthcare

As Steve Jobs said, “the biggest innovations of the 21st century will be at the intersection of biology and technology.” As these two become closely intertwined, innovative digital technologies emerge.

Here’s a glimpse at some of the greatest trends and innovations that are shaping and pushing forward pharma endeavours and digital health.

10-digital-health

Healthcare Chatbots

Given that there’s over one billion people using Facebook Messenger, chatbots built on this platform are an ideal solution that could significantly improve patients’ health as well as the communication with their doctors.

Medication adherence

According to a World Health Organization report,“adherence to long-term therapy for chronic illnesses in developed countries averages 50%” and “removing barriers to adherence must become a central component of efforts to improve population health worldwide.”

While apps may be one answer, they require installation and a change of context every time a user needs them. On the other hand, chatbots are extremely easy to use. Patients could scan a profile code from Messenger and immediately start talking to an adherence bot, without the need to reveal their identity or set up a separate account. Consequently, the bot would help the patient add their first medication, give details about the amounts he needs to take and the times. Then, the bot will send friendly reminders at the times they specified. All of this process shouldn’t take more than a few minutes.

Patient information

Bots could also collect patient information – symptoms, pain level, mood information, blood sugar levels- that could be discussed with the healthcare provider. The latter could request a full report from the bot prior to the patient’s appointment so that nothing is forgotten or overlooked.

As an example, there is Stuzo’s Labs Adherence Bot. Although it’s merely a prototype, the bot already has high chances of being successful.

Recently, Chinese search engine Baidu has launched a medical chatbot dubbed Melody designed to make diagnosing illnesses easier.

mHealth Sensors

Also knows as “beyond the pill” services, apps and wearables allow patients to monitor their health and symptoms outside of clinical environments, fact that will prove important when it comes to freeing hospital beds and increasing doctors’ availability.

In September 2015, the FDA accepted the first New Drug Application for a ‘digital’ medicine – the anti-psychotic drug Abilify had an ingestible sensor attached to monitor patient adherence. Such collaborations between pharma and tech are expected to boom within the next years.

Furthermore, pharma research institutes are leveraging mHealth technology to carry out clinical research. In that sense, smartphones with advanced sensors that can track movement, take measurements and record information are used to conduct studies that engage large numbers of people from wide geographical areas. Apple has several mHealth apps for clinical research, some are targeting Parkinson’s disease, diabetes, cardiovascular disease, while others focus on asthma and breast cancer.

Other devices such a smartwatches like Apple Watch or Samsung Gear and fitness bands (FitBit, Jawbone, Garmin) also have sensors capable of taking biometric readings. As they become more advanced, wearable devices will become a key asset in gathering clinical trial data remotely in real-time.

The fact that these devices are connected to the internet means that the information they gather can be synced with other devices or shared with doctors and researchers. This could mean that in the future, fewer patients will need to personally go to medical research centres or hospitals when participating in clinical trials, which could prompt a shift for pharma companies and CROs towards remote monitoring, as opposed to in-person meetings.

3D Printing

In March 2016, epilepsy drug Spritam became the first 3D printed drug to be approved by the FDA. The pill is manufactured by Aprecia Pharmaceuticals by spreading layers of the drug and building the pill through a three-dimensional printing process. The latter enables the use of a higher dose of medicine while keeping the pill porous enough to dissolve quickly.

Researchers at the School of Pharmacy of University College London are using a technique called “hot melt extrusion” to 3D-print pills in various shapes, spanning from pyramids to doughnuts. The form of the pill influences the rate of drug release. For example, a pyramid-shaped pill releases the drug slower than a cube or sphere and this enables absorption to be controlled.

3D printed drugs are not only set to change the way in which drugs are being manufactured, but also how they are administered. Hospitals could easily adjust doses depending on individual patients and their treatment.

Artificial Intelligence

Cognitive computing platforms such as IBM Watson have the capabilities to interact in natural language, process vast amounts of Big Data and understand patterns and insights while learning from each interaction. The Watson Health Cloud was launched in April 2015 as an open development platform for physicians, researchers, insurers, and companies.

By digesting and interpreting millions of pages of scientific literature, IBM Watson can assist pharma companies in the development of new drugs while repurposing existing ones. Johnson & Johnson is collaborating with the IBM Watson Discovery Advisor team to use Watson to develop and evaluate medications and other treatments, while Sanofi is looking into the discovery of alternative use cases for existing drugs (drug re-purposing).

These are only a few of the amazing trends and innovations that promise to influence not only the ways in which pharma companies and healthcare providers conduct their daily research and clinical trials but also the ways in which patients from all over the world cope with illnesses and follow treatment schemes. The future promises much more!

If you’re passionate about emerging trends and innovations in pharma and healthcare, these congresses should be on your list in 2017:

  1. ESMO 2017 Madrid, 8.- 12. September, 2017 -> http://bit.ly/2eIoDxQ
  2. ERS 2017 Milano, 9.- 13. September, 2017 -> http://bit.ly/2dh3f40
  3. EASD 2017 Lisbon, 11. – 15. September, 2017 -> http://bit.ly/2dZ4sgI